Current Therapeutic Opportunities for Estrogen Receptor Mutant Breast Cancer
2024
Current Therapeutic Opportunities for Estrogen Receptor Mutant Breast Cancer
publication
10 minutes
Evidence: moderate
Author Information
Author(s): Palaniappan Murugesan
Primary Institution: Baylor College of Medicine
Hypothesis
The study investigates the therapeutic strategies for targeting estrogen receptor mutants in breast cancer.
Conclusion
The review highlights the need for new drugs targeting estrogen receptor mutants due to their role in endocrine-resistant metastatic breast cancer.
Supporting Evidence
- Estrogen receptor α (ERα) mutations are common in endocrine-resistant metastatic breast cancer.
- Y537S and D538G mutations lead to higher transcriptional activity of ERα.
- New drugs targeting ER mutants are needed due to the ineffectiveness of traditional therapies.
Takeaway
Some breast cancers have mutations that make them resistant to standard treatments, so new drugs are being developed to target these mutations.
Methodology
The review summarizes recent preclinical and clinical trials targeting estrogen receptor mutant breast cancer.
Limitations
The review does not provide new experimental data but summarizes existing studies.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website